Date: 2016-05-18
Type of information: Results
phase: preclinical
Announcement: results
Company: Anavex Life Sciences (USA - NY)
Product: ANAVEX2-73 (tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride)
Action
mechanism: Anavex2-73 is an agonist of the intracellular sigma-1 chaperone protein. The compound is a mixed muscarinic receptor/sigma 1 ligand. It has been reported to have memory-preserving and neuroprotective effects in mice treated with the muscarinic receptor antagonist scopolamine, with synthetic ABêta oligomer injection, or with the NMDA receptor agonist dizocilpine. A recent study suggested that Anavex 2-73 may block tau hyperphosphorylation.
Disease: infantile spasms
Therapeutic area: CNS diseases
Country:
Trial details:
Latest
news: * On May 18, 2016, Anavex Life Sciences announced that treatment with ANAVEX 2-73 significantly reduced the number of spasms in an animal model with infantile spasms (epileptic spasms) in infant rats. In the preclinical study, following prenatal priming with betamethasone in infant rats, spasms were recorded for 90 minutes following postnatal trigger of spasms with NMDA injection. Treatment with ANAVEX 2-73 significantly reduced the number of spasms by 55 percent compared to vehicle (p=0.0002). The study was sponsored and performed by Libor Velisek, MD, PhD, Professor of Cell Biology & Anatomy, Pediatrics, and Neurology and his laboratory at New York Medical College (NYMC). The infantile spasms rat model represents a clinically relevant animal model of infantile spasms since the phenotype is developmentally specific and semiologically similar to human infantile spasms, including clustering of spasms. The phenotype of spasms persists only up to 21 days of age in rats (correlating with human infancy and early childhood). Further, EEG features correspond well to human infantile spasms, with interictal high amplitude asynchronous waves similar to hypsarrhythmia and ictal EEG suppression similar to electrodecrements.
